[go: up one dir, main page]

BRPI0414719A - therapeutic regimens for administering drug combinations - Google Patents

therapeutic regimens for administering drug combinations

Info

Publication number
BRPI0414719A
BRPI0414719A BRPI0414719-7A BRPI0414719A BRPI0414719A BR PI0414719 A BRPI0414719 A BR PI0414719A BR PI0414719 A BRPI0414719 A BR PI0414719A BR PI0414719 A BRPI0414719 A BR PI0414719A
Authority
BR
Brazil
Prior art keywords
drug combinations
administering drug
therapeutic regimens
administering
formulated
Prior art date
Application number
BRPI0414719-7A
Other languages
Portuguese (pt)
Inventor
Mahesh Padval
Peter Elliott
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46123823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0414719(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/670,488 external-priority patent/US20040220153A1/en
Priority claimed from US10/777,517 external-priority patent/US20040229849A1/en
Priority claimed from US10/777,518 external-priority patent/US20040224876A1/en
Priority claimed from US10/944,574 external-priority patent/US20050137185A1/en
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of BRPI0414719A publication Critical patent/BRPI0414719A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)

Abstract

"REGIMES TERAPêUTICOS PARA ADMINISTRAR COMBINAçõES DE FáRMACOS". A presente invenção caracteriza regimes de dosagem para a administração de combinação de terapias, em que um dos fármacos da combinação é formulado para liberação gradual, ou administrado repetidamente, e composições relacionadas para a mesma."THERAPEUTIC SCHEMES FOR ADMINISTERING DRUG COMBINATIONS". The present invention features dosage regimens for combination therapy administration, wherein one of the combination drugs is formulated for gradual release, or repeatedly administered, and related compositions thereof.

BRPI0414719-7A 2003-09-24 2004-09-23 therapeutic regimens for administering drug combinations BRPI0414719A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US10/670,488 US20040220153A1 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US51241503P 2003-10-15 2003-10-15
US52044603P 2003-11-13 2003-11-13
US10/777,517 US20040229849A1 (en) 2002-09-24 2004-02-12 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US10/777,518 US20040224876A1 (en) 2003-02-14 2004-02-12 Combination therapy for the treatment of immunoinflammatory disorders
US55749604P 2004-03-30 2004-03-30
US10/944,574 US20050137185A1 (en) 2003-09-18 2004-09-17 Combinations of drugs for the treatment of neoplasms
US10/947,455 US20050153947A1 (en) 2002-09-24 2004-09-20 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
PCT/US2004/031195 WO2005030132A2 (en) 2003-09-24 2004-09-23 Therapeutic regimens for administering drug combinations

Publications (1)

Publication Number Publication Date
BRPI0414719A true BRPI0414719A (en) 2006-11-21

Family

ID=46123823

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414719-7A BRPI0414719A (en) 2003-09-24 2004-09-23 therapeutic regimens for administering drug combinations

Country Status (10)

Country Link
EP (1) EP1675550A4 (en)
JP (1) JP2007517766A (en)
KR (1) KR20060076319A (en)
AU (1) AU2004275777A1 (en)
BR (1) BRPI0414719A (en)
CA (1) CA2538023A1 (en)
IS (1) IS8413A (en)
MX (1) MXPA06003320A (en)
NO (1) NO20061284L (en)
WO (1) WO2005030132A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
JP5069907B2 (en) 2003-09-17 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Fused heterocyclic compounds
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
MXPA06013463A (en) * 2004-05-17 2007-03-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders.
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
TW200932240A (en) * 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
KR101546596B1 (en) 2011-01-04 2015-08-21 이스타 파머슈티컬즈, 인크. Bepotastine compositions
IL302036A (en) * 2020-10-14 2023-06-01 C4 Therapeutics Inc Tricyclic compounds for breaking down neo-substrates for medical treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618677A (en) * 1984-05-31 1986-10-21 Boehringer Ingelheim Limited Substituted phenylalkyl-(piperazinyl or homopiperazinyl)alkyl-thiols and -thiocarbamates useful for the treatment of immunological, inflammatory, and allergic disorders
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
JP3962108B2 (en) * 1995-04-03 2007-08-22 中外製薬株式会社 Sucralfate-containing pharmaceutical composition
AU782971B2 (en) * 1999-12-23 2005-09-15 Nicox S.A. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
IL159771A0 (en) * 2001-07-09 2004-06-20 Combinatorx Inc Combinations for the treatment of inflammatory disorders
EP1350512A1 (en) * 2002-04-03 2003-10-08 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
CA2481377A1 (en) * 2002-04-04 2003-10-16 Dr. Reddy's Laboratories Ltd. Antihistamine-decongestant pharmaceutical compositions
EP1503739A4 (en) * 2002-04-15 2006-06-21 Adams Respiratory Therapeutics Sustained release of guaifenesin combination drugs
AU2003255890A1 (en) * 2002-08-23 2004-03-11 Ranbaxy Laboratories Limited Nitrofurantoin controlled release dosage form
BR0314713A (en) * 2002-09-24 2005-07-26 Combinatorx Inc Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.

Also Published As

Publication number Publication date
KR20060076319A (en) 2006-07-04
NO20061284L (en) 2006-06-22
AU2004275777A1 (en) 2005-04-07
MXPA06003320A (en) 2006-06-08
EP1675550A4 (en) 2007-10-10
JP2007517766A (en) 2007-07-05
CA2538023A1 (en) 2005-04-07
WO2005030132A2 (en) 2005-04-07
WO2005030132A3 (en) 2006-10-12
EP1675550A2 (en) 2006-07-05
IS8413A (en) 2006-04-12

Similar Documents

Publication Publication Date Title
Helander et al. Multimodal analgesia, current concepts, and acute pain considerations
BR0110877A (en) Methods of treating primary cancer, increasing the dosage of a topoisomerase inhibitor, reducing or preventing an adverse effect associated with chemotherapy and radiation therapy, increasing the therapeutic efficacy of a topoisomerase inhibitor, and protecting a cancer patient from adverse effects associated with administration of an anti-cancer drug, pharmaceutical composition, dosage form, and kit for use in cancer treatment
BR0009647A (en) Docetaxel in combination with rhumab her2 for the treatment of cancers
ES2153338T1 (en) IMPROVED DOSAGE OF MULTIPLE DOSES OF MEDICINES.
BRPI0418029B8 (en) stable liquid pharmaceutical formulation suitable for parenteral administration comprising a cd40 agonist antibody
BRPI0408999A (en) compressed prolonged oral release multiparticulate tablets
BR0116607A (en) Glycopyranosyloxypyrazole derivatives and their use in medicines
BRPI0518622A2 (en) uses of interleukin-1 (il-1r1) type 1 receptor antagonists for the manufacture of a medicament for the treatment of a respiratory disease; A pharmaceutical composition comprising an IL-1R1 antagonist and a physiologically acceptable carrier and drug delivery device.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
BRPI0513200A (en) use of an anti-igf-1r antibody in the preparation of a medicament for combined treatment for nonhematological malignancies
BRPI0415649A (en) method for treating, preventing, modifying or administering pain and pharmaceutical composition
BR9909903A (en) Maximum effectiveness of substances used to improve health and well-being
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
BRPI0418026A (en) phenylalanine derivatives or pharmaceutically acceptable salts thereof, pharmaceutical composition, alpha4 integrin antagonist, and therapeutic or preventative agent for diseases
UY27533A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING OXIBUTININE
BRPI0411079A (en) pharmaceutical compositions comprising atorvastatin manufactured without granulation
BRPI0411451A (en) oral dosage forms of memantine
BRPI0519171A2 (en) ophthalmic drug delivery device
ATE298324T1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
BRPI0414719A (en) therapeutic regimens for administering drug combinations
BRPI0519656A2 (en) combination therapy comprising telmisartan and hydrochlorothiazide
BRPI0607172A2 (en) method for administering at least one pharmaceutically active substance to a patient, combining medicaments and using at least one pharmaceutically active substance for the manufacture of a combination of medicaments
FR2878158B1 (en) ORAL PHARMACEUTICAL FORM, SOLID MICROPARTICULAR DESIGNED TO PREVENT MEASUREMENT
BRPI0510895A (en) 10-propargyl-10-deazaaminopterin pharmaceutical formulation for t-cell lymphoma treatment
BRPI0518741A2 (en) use of a combination of a drug directly metabolised by ugt1a1 or a pharmaceutically acceptable salt thereof and atazanavir or a pharmaceutically acceptable salt thereof, and a pharmaceutical combination for oral administration to a mammal

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.